Mechanism of Action
Antimicrobial Mechanisms
Defensins kill bacteria, fungi, and enveloped viruses through multiple mechanisms: (1) Membrane permeabilization via cationic peptide insertion into anionic microbial membranes; (2) Inhibition of cell wall synthesis by binding lipid II (a peptidoglycan precursor transporter); (3) Intracellular targeting after membrane translocation (DNA/RNA damage, enzyme inhibition). Alpha-defensins act primarily extracellularly; some beta-defensins also modulate intracellular targets.
Immunomodulatory Roles
Beyond direct killing, defensins are chemoattractants for dendritic cells, T cells, and monocytes. hBD-2 activates Toll-like receptor 4 (TLR4) on immature dendritic cells, bridging innate and adaptive immunity. HNP-1 inhibits HIV-1 replication by blocking virus-cell fusion independent of membrane lysis. Alpha-defensins suppress cortisol synthesis (glucocorticoid-inhibiting role in stress contexts).
Research Summary
Mucosal Defense and IBD
Clinical EvidencePaneth cell alpha-defensins HD-5 and HD-6 are critical for intestinal microbial homeostasis. Deficiency in HD-5/HD-6 expression is associated with Crohn's disease susceptibility. Mouse models with transgenic human HD-5 show improved resistance to intestinal pathogens. Defensin deficiency has been proposed as a contributing factor to dysbiosis in IBD.
Antiviral Activity
PreclinicalMultiple defensins show antiviral activity against HIV, HSV, influenza, adenovirus, and SARS-CoV-2 in cell culture. Alpha-defensins block viral attachment and entry. Human theta-defensin (retrocyclin, a pseudogene in humans) shows exceptionally broad antiviral activity; efforts to restore its expression via pseudogene read-through or synthetic production are ongoing.
Wound Healing
PreclinicalBeta-defensins (hBD-2, hBD-3) are induced at wound sites and promote re-epithelialization by activating keratinocyte migration via EGF receptor transactivation. They also inhibit biofilm formation on wound surfaces. Topical defensin application has been tested in preclinical wound models with accelerated healing outcomes.
Calculate your Defensin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| MIC determination (bacteria/fungus) | 0.1-50 ug/mL | Single plate read | In vitro (broth microdilution) |
| Wound healing (mouse model) | 5-50 ug per wound | Daily x 7 days | Topical |
| DC chemotaxis assay | 0.1-1 uM | Single time-point | In vitro migration assay |
No systemic human dosing protocols. Defensins are research tools and topical candidate compounds. Their endogenous roles are established; exogenous therapeutic administration is in early-stage development.
Interactions
Safety Profile
Endogenous defensins are produced safely in human tissues. Exogenous defensin peptides show cytotoxicity to mammalian cells at concentrations 10-50x the antimicrobial MIC, providing a therapeutic window for topical use. Systemic defensin administration is not established for humans. In vivo studies in mice with systemic defensin infusion show inflammatory cytokine activation that limits systemic utility. Topical and mucosal delivery are the most promising routes.
References
- [1]Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3(9):710-720.
- [2]Wehkamp J, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA. 2005;102(50):18129-18134.
- [3]Lehrer RI, Lu W. Alpha-defensins in human innate immunity. Immunol Rev. 2012;245(1):84-112.